Toxicology

Philip Morris International Demonstrates Clear Progress Toward Its Purpose as It Releases 2023 Integrated Report

Retrieved on: 
Thursday, March 28, 2024
Sustainability, Environment, Environmental, Social and Governance (ESG), Tobacco, Professional Services, Consumer, Other Consumer, Retail, Smoke, Philip Morris International, Integration, Materiality, History, Sale, Child, Science, Quality of life, GRI, Intellectual property, United Nations Global Compact, Marketing, Dow Jones, Science Based Targets initiative, FLAG, Information, Woman, ISS, Privacy, Food, Prevalence, ESG, PMI, Research, Classification, Heated tobacco product, Investment, Dow Jones Sustainability Indices, Targets, Farmer, COVID-19, Life, ZYN, Biodiversity, Smoking, Water, IQOS, Toxicology, World Bank

Please visit pmi.com/sustainability to learn more, and read the full 2023 Integrated Report , case studies and market stories , and the Sustainability KPI Protocol 2023 .

Key Points: 
  • Please visit pmi.com/sustainability to learn more, and read the full 2023 Integrated Report , case studies and market stories , and the Sustainability KPI Protocol 2023 .
  • 2 For definition of net revenues related to smoke-free products, see Glossary available on pages 208-212 of PMI Integrated Report 2023.
  • 3 For definition of available for sale, see Glossary available on pages 208-212 of PMI Integrated Report 2023.
  • For definition of low- and middle-income markets, see Glossary available on pages 208-212 of PMI Integrated Report 2023.

U.S. Clinical Laboratory Tests Market Outlook & Forecast 2024-2029 Featuring Prominent Vendors - Eurofins Scientific, Laboratory Corp of America, Mayo Clinic, OPKO, Quest Diagnostics, Siemens, Sonic - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 27, 2024
Other Health, Research, Telemedicine, Virtual Medicine, Biometrics, Medical Devices, Hospitals, Health Technology, Clinical Trials, Science, Biotechnology, Medical Supplies, Health, Cloud, Hospital, Diagnosis, Machine learning, COVID, Hematology, Disease, COVID-19, Patient, Pharmacy, Public, AI, Laboratory, Insurance, Labcorp, City, Robotics, Cloud computing, Microbiology, Antibody, Toxicology, Medicare, Collection, USD, Data management, Government, Endocrinology, Physician, Immunochemistry, Quest Diagnostics

Based on that, the competitive landscape in the country for the clinical laboratory test market is highly localized and challenging.

Key Points: 
  • Based on that, the competitive landscape in the country for the clinical laboratory test market is highly localized and challenging.
  • The U.S. clinical laboratory tests market by providers is segmented into hospital-based clinical laboratories, independent laboratories, physician office laboratories, and others.
  • The U.S. clinical laboratory tests market by test type is segmented into clinical & immunochemistry, molecular diagnostics, hematology, microbiology & cytology, and toxicology.
  • Clinical and immunochemistry types of clinical lab tests account for a higher market share and dominate other tests.

Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, Health, Clinical Trials, Research, Conference, TSX Venture Exchange, MSCL, Regeneration, CFO, G&A, Toronto Stock Exchange, Muscular dystrophy, Doctor of Philosophy, MD, Senior, MBA, GMP, IND, Bank statement, TSX, Regenerative medicine, Duchenne muscular dystrophy, Facioscapulohumeral muscular dystrophy, Investment, Chemistry, Toxicology, Therapy, AAK1, OTCQB, FDA, GLP, Animal, DMD, FSHD, Hand, Episcopal conference, Food, CPA, Pharmaceutical industry

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the year ended December 31, 2023.

Key Points: 
  • Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights for the year ended December 31, 2023.
  • Subsequent to the year end, on March 4, 2024, Satellos announced positive preclinical data presented at the Muscular Dystrophy Association Clinical and Scientific Conference.
  • Satellos also announced that SAT-3247 would be nominated as its lead development candidate with SAT-3153 becoming the backup development candidate.
  • Satellos’ audited financial statements for the year ended December 31, 2023, and the related management’s discussion and analysis (MD&A) will be available on SEDAR+ at www.sedarplus.ca .

Philip Morris International Names New External Affairs Leader

Retrieved on: 
Tuesday, March 26, 2024
Tobacco, Retail, Smoke, Physics, Foreign policy, Philip Morris International, Aristotle University of Thessaloniki, Public, PMI, Research, Policy, Sale, Life, Kent University, Senior, ZYN, IQOS, Toxicology, Economics, Coca-Cola Hellenic Bottling Company, Food

Philip Morris International Inc. (PMI) (NYSE: PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024.

Key Points: 
  • Philip Morris International Inc. (PMI) (NYSE: PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024.
  • “He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes.
  • “Leading our dynamic External Affairs function globally is an enormous honor,” said Christos Harpantidis.
  • “Under Christos’ leadership, I believe that the External Affairs function will ensure that this positive momentum is maintained and further amplified.”
    Philip Morris International (PMI) is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector.

Alliance for Food and Farming: Studies, Government Data Discredit “Dirty Dozen” List

Retrieved on: 
Monday, March 18, 2024
FDA, Retail, Other Consumer, Organic Food, General Health, Women, Parenting, Men, Agriculture, Natural Resources, Supermarket, Family, Food, Beverage, Consumer, Health, Eating, Pesticide, USDA, Organization, Farmer, Vegetable, Risk, Journal, Research, Detergent, EWG, Poverty, PDP, DBA, Diet, Risk assessment, EPA, CDC, Pesticide Data Program, Water, Fruit, Safety, Toxicology, Work

The research also found that the list authors follow no scientifically established methodology in the development of their list.

Key Points: 
  • The research also found that the list authors follow no scientifically established methodology in the development of their list.
  • From Environmental Working Group’s (EWG) “Dirty Dozen” report: “The Shoppers Guide does not incorporate risk assessment into the calculations.
  • The Alliance for Food and Farming is a non-profit organization formed in 1989 which represents organic and conventional farmers.
  • Alliance contributors are limited to farmers of fruits and vegetables, companies that sell, market or ship fruits and vegetables or organizations that represent produce farmers.

International Collaboration on Cosmetics Safety Announces Newly Elected Board Officers

Retrieved on: 
Thursday, March 14, 2024
Other Consumer, Research, Professional Services, Philanthropy, Consumer, Cosmetics, Environmental, Social and Governance (ESG), Other Philanthropy, Retail, Science, Unilever, Growth, ICCS, Toxicology, Detergent

The International Collaboration on Cosmetics Safety (ICCS) announced today the election of its new officers of the Board of Directors.

Key Points: 
  • The International Collaboration on Cosmetics Safety (ICCS) announced today the election of its new officers of the Board of Directors.
  • “I look forward to working with the officers who bring strong leadership and advocacy to position ICCS for continued growth and impact.
  • The Board chair elected is Charles François Gaudefroy who has more than 30 years of experience in research and development for cosmetics, detergents, and foods with Unilever.
  • The other officers elected joining Charles François are:
    Stéphane Dhalluin, Ph.D., Global Head and Director of Human and Environmental Safety Evaluation, L’Oréal
    Jon Lalko, Ph.D., Executive Fellow – Product Safety and Toxicology, Estée Lauder

UC Berkeley Launches New Molecular Therapeutics Initiative to Accelerate Drug Discovery

Retrieved on: 
Thursday, March 14, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, University, Education, Gene editing, Data science, Drug discovery, Patient, UCB, UC, Artificial intelligence, Chemical biology, Proximity, Cell biology, Cancer, Faculty, Protein, Student, MTI, Doctor of Philosophy, Therapy, Howard Hughes Medical Institute, MTX, University of California, Berkeley, Toxicology, DSM-IV codes, Pharmaceutical industry

The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.

Key Points: 
  • The University of California, Berkeley Molecular Therapeutics (MTx) division of the Molecular & Cell Biology department today announced the launch of a new initiative to accelerate drug discovery at the interface of academia and biotech.
  • The UC Berkeley Molecular Therapeutics Initiative (MTI) will create a foundational bridge between fundamental research in rare neurological and metabolic diseases and drug discovery to identify and accelerate novel therapeutic modalities into the clinic.
  • “UC Berkeley is an international nucleus for scientific breakthroughs, such as gene editing and immuno-oncology.
  • “In this way, we are not only advancing R&D but also democratizing it by building industry connections for emerging researchers interested in pursuing a biotech career.”
    The UC Berkeley Molecular Therapeutics Initiative (MTI) seeks to accelerate drug discovery efforts by creating therapeutic modalities that overcome challenges in druggability and address unmet medical need.

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 13, 2024
Health, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, STAC, Gene, Orphan drug, ALTA, Haemophilia A, BBB, Patient, Health care, Quality of life, IND, Male, ERT, Investment, Therapy, Fabry disease, Plasma, Kite, Gene expression, Partnership, Central nervous system, Novartis, CNS, Pivotal, EMA, Prion, STAAR, Enzyme replacement therapy, Biogen, Tauopathy, Workforce, BLA, AAV, Sanofi, Research, DRG, Neuron, Hematology, FDA, DSM-IV codes, Brain, Sangamo Therapeutics, MAA, Haemophilia, CTA, Mouse, Female, Traffic barrier, Sodium, MHRA, Excipient, Society, Spinal cord, Toxicology, Sigma-Aldrich, Liver, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline.
  • “In 2023, Sangamo announced the prioritization of its pipeline programs that support our focus as a neurology-focused genomic medicine company,” said Sandy Macrae, Chief Executive Officer of Sangamo.
  • STAC-BBB was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues.
  • Revenues for the fourth quarter ended December 31, 2023 were $2.0 million, compared to $27.2 million for the same period in 2022.

Philip Morris International Launches New IQOS ILUMA i in Japan to Accelerate the Achievement of a Smoke-Free Future

Retrieved on: 
Wednesday, March 13, 2024
Technology, Tobacco, Retail, Consumer Electronics, Smoke, Philip Morris International, Taste, Olczak, Science, Risk, PMI, Research, Smoker, Sale, Life, ZYN, System, Nicotine, IQOS, Toxicology, Q3, Aluminium, Government, Food

1 tobacco heating system.1 The launch also marks the 10-Year anniversary of IQOS, originally launching in Nagoya, Japan in 2014.

Key Points: 
  • 1 tobacco heating system.1 The launch also marks the 10-Year anniversary of IQOS, originally launching in Nagoya, Japan in 2014.
  • Within 10 years, IQOS net revenues have surpassed those for Marlboro, making it the number one international nicotine brand and accelerated the decline of cigarettes in many countries.
  • In Japan, for example, nearly one-third of adult smokers are using IQOS2 and cigarette sales have declined much more rapidly since heated tobacco was launched.
  • It is important that others—like government authorities and regulators—embrace the opportunity offered by innovation and science to benefit the world.”
    The IQOS ILUMA i series offers three devices in Japan: IQOS ILUMA i PRIME, IQOS ILUMA i and IQOS ILUMA i ONE.

Parental avoidance of toxic exposures could help prevent autism, ADHD in children, new study shows

Retrieved on: 
Thursday, March 28, 2024
Pesticide, Sensitivity, Xenobiotic, Collaborative writing, Prevalence, ADHD, Cell, Risk, Inflammation, Patient, SAN, School, Anglo-French Wars, Tissue, Research, Miller, Child, Breast, Virus, University, Wane, Doctor of Philosophy, Pregnancy, Causality, Attention deficit hyperactivity disorder, Gulf War, B cell, EPA, CDC, University of Texas System, Fire, Toxicology, Workforce, Public health, TILT, Spectrum, Family, Histamine, Vaccine

SAN ANTONIO, March 27, 2024 /PRNewswire-PRWeb/ -- Autism and attention deficit hyperactivity disorder (ADHD) may be preventable if parents avoid toxic exposures and adopt interventions such as environmental house calls, according to a published study led by researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio).

Key Points: 
  • The findings build on a 2015 study by UT Health San Antonio that first linked chemical intolerance in patients with the risk of their children developing autism and ADHD.
  • "Up to now, most interventions have been behavioral or medical, after a child is diagnosed."
  • Still, they wrote, "The implications of this study, if confirmed, could be significant for preventive measures and early intervention strategies in families with parental chemical intolerance.
  • And the prevalence of ADHD has risen to one in eight children, also according to the CDC.